Arcturus Therapeutics (ARCT) said late Monday the US Food and Drug Administration has given the clearance to begin the clinical study for its H5N1 pandemic flu vaccine candidate ARCT-2304.
The company said the trial, which is funded by the Biomedical Advanced Research and Development Authority, is designed to enroll around 200 healthy adults in the US.
The phase 1 trial aims to evaluate the safety, reactogenicity, and immunogenicity of the "self-amplifying" mRNA vaccine, Arctus said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments